The meeting on Friday capped a tumultuous few weeks for Novo after a dispute over the pace of change at the struggling maker of the blockbuster drugs Ozempic and Wegovy led to more than half the supervisory board resigning last month. The outcome was a foregone conclusion as Sorensen, who ran Novo for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of the company’s voting rights. In the weeks since Doustdar and Sorensen took the reins, Novo has announced layoffs for 11% of the company, axed longtime pet projects such as an effort to cure diabetes using stem cells, and started the bidding war with Pfizer.
Author: list.metadata.agency
Published at: 2025-11-15 20:24:35
Still want to read the full version? Full article
